The administration of mAbs blocking CTLA-4, PD-1 or PD-L1 allows for the generation of a sustained and specific CTL response capable of tumor cell lysis (Fig. 1B)[20, 26, 28]. The gene discussed is CTLA4; the disease is neoplasm.